Lilly says Omvoh is still clearing UC after 4 years

Four years in, and Omvoh is still hanging on

Eli Lilly dropped fresh long-term data on Omvoh, its IL-23p19 antibody for ulcerative colitis, and the headline is simple: durability. In the LUCENT-3 open-label extension study, 63.5% of patients who hit disease clearance at one year were still there four years later.

That matters because “disease clearance” in UC isn’t a casual pat on the back. It means the patient has checked a pretty brutal trio of boxes at once: symptoms, endoscopy, and histology all looking good. In other words, this isn’t just vibes and a better day at the office.

Why investors should care

Long-term data is where a lot of drugs either look sturdy or start wobbling like a shopping cart with one bad wheel. Showing four-year durability gives Lilly another proof point that Omvoh could be a durable growth engine in inflammatory bowel disease, a market where physicians tend to care a lot about staying power.

For Lilly, every solid data update is part of the bigger portfolio story: the company is already riding the GLP-1 wave, but it keeps trying to prove it’s more than a one-trick pony. A drug like Omvoh adds depth, and depth is what helps big pharma keep the party going after the headline-grabbing obesity numbers fade a bit.

The takeaway

This is not an instant revenue moonshot, but it’s the kind of clinical evidence that can support adoption, payer confidence, and future commercial momentum. Big picture: when a drug keeps working after four years, investors tend to perk up — because consistency is what turns a decent asset into a franchise.